NCT06964711View on ClinicalTrials.gov

GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

GW117 ODT

Sublingual route ， 0.5mg/1mg/2mg/4mg，QD

DRUG

Placebo

GW117 Placebo matching for Sublingual route ，QD

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Beijing Greatway Pharmaceutical Technology Co.,Ltd.

INDUSTRY

NCT06964711 - GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects | Biotech Hunter | Biotech Hunter